Women shown in the pictures are not FEM-PrEP participants
FEM-PrEP
FEM-PrEP was a randomized, placebo-controlled trial to assess the safety and effectiveness of a daily oral dose of tenofovir disoproxil fumarate and emtricitabine for HIV prevention among women. Read more
Publications
Click here to learn about FEM-PrEP manuscripts related to adherence, clinical outcomes, community engagement, contraception and pregnancy, laboratory, participant recruitment, risk perceptions and sexual behaviors, and PrEP rollout. Read more
Related Research & Information
FHI 360 and others are currently or have recently conducted complementary research on ARV-based HIV prevention products. Read more
